Share on StockTwits

Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by research analysts at Gabelli from a “buy” rating to a “hold” rating in a report released on Tuesday.

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 1.64 on Tuesday. Lexicon Pharmaceuticals has a 1-year low of $1.25 and a 1-year high of $3.18. The stock has a 50-day moving average of $1.56 and a 200-day moving average of $1.62. The company’s market cap is $844.3 million.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.05). The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.13 million. The company’s quarterly revenue was up 215.9% on a year-over-year basis. Analysts expect that Lexicon Pharmaceuticals will post $-0.20 EPS for the current fiscal year.

Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.